Outlook Therapeutics (OTLK) announced that the FDA has issued a complete response letter to the ONS-5010/Lytenava biologics ...
Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...
The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials ...
Find out how higher dose aflibercept may reduce injection burden while preserving vision in retinal vasculopathy.
Ohm J . Über die Behandlung der Netzhautablosung durch operative Entleerung der subretinalen Flussigkeit und Einspritzung von Luft in den Glaskörper. Graefes Arch Klin Exp Ophthalmol 1911;79:442–50.
EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...
The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...
TipRanks on MSN
Theriva Biologics gains EMA backing for VCN-01 phase 3
Theriva Biologics ( ($TOVX) ) just unveiled an update. On December 29, 2025, Theriva Biologics reported that it received positive Scientific ...
An overview of the top 10 stories from Optometry Times in 2025.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA ...
A high-level overview of 4D Molecular Therapeutics, Inc. (FDMT) stock. View (FDMT) real-time stock price, chart, news, analysis, analyst reviews and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback